BioSpace News Archive

Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022, after the market close.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Annexon, Inc. (Nasdaq: ANNX), today outlined progress across its broad pipeline of fit-for-purpose product candidates and anticipated clinical milestones, and reported second quarter 2022 financial results.

FibroGen, Inc. reported financial results for the second quarter 2022 and provided an update on the company’s recent developments.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended June 30, 2022.

Forecast to 2030,’ thoroughly examines the Inguinal Hernia Device industry to provide essential data & information for the targeted readers.

Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the second quarter and first half of 2022.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported financial results for the second quarter ended June 30, 2022 and provided clinical development and operational highlights.